Literature DB >> 2295114

Distribution of doxorubicin to normal breast and tumour tissue in patients undergoing mastectomy.

S Stallard1, J G Morrison, W D George, S B Kaye.   

Abstract

Response to cytotoxic agents is assumed to be related to the concentration of drug achieved within tumour tissue. It is also often assumed that, given similar tissue concentrations of drug, normal tissues are less responsive to the same cytotoxic agents. This can partly be explained by the number of cells in normal tissues that are differentiated. These non dividing cells, in a stable testing phase of the cell cycle (G0) are less susceptible to cytotoxic damage. Little is actually known about the relationship between tumour drug concentrations and those in the tissue of the tumour-bearing organ. In this study, we compared doxorubicin concentrations in paired samples of tumour and normal breast tissue from 17 previously untreated women undergoing mastectomy. The relative cellularities of both specimens were estimated by measuring their DNA content. There was wide variation in intra-tumoural doxorubicin concentrations (range, 220-1,590 ng/g). Normal tissue also showed marked inter-patient variation (range, 81-1,000 ng/g). For a single patient the tumour drug concentrations were significantly higher than those in normal breast tissue (P less than 0.05), and tumour: normal tissue ratios ranged from 1.27 to 8.30. Where doxorubicin concentration was expressed in terms of the relative cellularity of the tissues, there was no significant difference between, drug concentrations in the tumour and those in normal breast tissue (tumour: normal ratios, 1.1:1.8). There was a significant correlation (r = 0.76, P less than 0.05) between peak serum values and tumour concentrations of drug. No correlation was found between drug concentrations achieved and the histological grade or oestrogen receptor status of the breast cancer.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2295114     DOI: 10.1007/bf00684887

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  26 in total

1.  Expression of a multidrug-resistance gene in human tumors and tissues.

Authors:  A T Fojo; K Ueda; D J Slamon; D G Poplack; M M Gottesman; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

2.  Analysis of the pharmacokinetic characteristics, pharmacological and chemotherapeutic activity of 14-Hydroxy-daunomycin (Adriamycin), a new drug endowed with an antitumour activity.

Authors:  E Arena; N D'Alessandro; L Dusonchet; N Gebbia; F Gerbasi; M Palazzoadriano; A Raineri; L Rausa; E Tubaro
Journal:  Arzneimittelforschung       Date:  1971-08

3.  Comparative pharmacokinetics of daunomycin and adriamycin in several animal species.

Authors:  D W Yesair; E Schwartzbach; D Shuck; E P Denine; M A Asbell
Journal:  Cancer Res       Date:  1972-06       Impact factor: 12.701

4.  Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemic lymphoblasts.

Authors:  W T Beck; T J Mueller; L R Tanzer
Journal:  Cancer Res       Date:  1979-06       Impact factor: 12.701

5.  Adriamycin and mitomycin C as initial chemotherapy for advanced breast cancer.

Authors:  S A Amiel; J F Stewart; H M Earl; R K Knight; R D Rubens
Journal:  Eur J Cancer Clin Oncol       Date:  1984-05

6.  Distribution of adriamycin in cancer patients: tissue uptakes, plasma concentration after IV and hepatic IA administration.

Authors:  Y T Lee; K K Chan; P A Harris; J L Cohen
Journal:  Cancer       Date:  1980-05-01       Impact factor: 6.860

7.  Prediction of adriamycin disposition in cancer patients using a physiologic, pharmacokinetic model.

Authors:  K K Chan; J L Cohen; J F Gross; K J Himmelstein; J R Bateman; Y Tsu-Lee; A S Marlis
Journal:  Cancer Treat Rep       Date:  1978-08

8.  Serum and tissue concentrations of doxorubicin after IV administration of doxorubicin or doxorubicin-DNA complex to patients with gastrointestinal cancer.

Authors:  P Gunvén; N O Theve; C Peterson
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

9.  Adriamycin alone or combined with vincristine in the treatment of advanced breast cancer.

Authors:  R Steiner; J F Stewart; B M Cantwell; M J Minton; R K Knight; R D Rubens
Journal:  Eur J Cancer Clin Oncol       Date:  1983-11

10.  A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma.

Authors:  J Carmo-Pereira; F O Costa; E Henriques; F Godinho; M G Cantinho-Lopes; A Sales-Luis; R D Rubens
Journal:  Br J Cancer       Date:  1987-10       Impact factor: 7.640

View more
  7 in total

Review 1.  Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies.

Authors:  Laleh Amiri-Kordestani; Agnes Basseville; Karen Kurdziel; Antonio Tito Fojo; Susan E Bates
Journal:  Drug Resist Updat       Date:  2012-03-29       Impact factor: 18.500

2.  DNA from dead cancer cells induces TLR9-mediated invasion and inflammation in living cancer cells.

Authors:  Johanna Tuomela; Jouko Sandholm; Mika Kaakinen; Ankita Patel; Joonas H Kauppila; Joanna Ilvesaro; Dongquan Chen; Kevin W Harris; David Graves; Katri S Selander
Journal:  Breast Cancer Res Treat       Date:  2013-11-10       Impact factor: 4.872

3.  Epirubicin as a single agent therapy for the treatment of breast cancer--a pharmacokinetic and clinical study.

Authors:  S Eksborg; L Hardell; N O Bengtsson; M Sjödin; B Elfsson
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

4.  Zebularine and trichostatin A sensitized human breast adenocarcinoma cells towards tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-induced apoptosis.

Authors:  Wei Yang Kong; Zong Yang Yee; Chun Wai Mai; Chee-Mun Fang; Syahril Abdullah; Siew Ching Ngai
Journal:  Heliyon       Date:  2019-09-19

5.  Tripeptide tyroserleutide plus doxorubicin: therapeutic synergy and side effect attenuation.

Authors:  Zhi-feng Zhu; Li-juan Chen; Rong Lu; Jing Jia; Yu Liang; Qiong Xu; Chun-lei Zhou; Li Wang; Song Wang; Zhi Yao
Journal:  BMC Cancer       Date:  2008-11-25       Impact factor: 4.430

6.  Visualisation of doxorubicin in human and animal tissues and in cell cultures by immunogold-silver staining.

Authors:  H P Henneberry; G W Aherne
Journal:  Br J Cancer       Date:  1992-01       Impact factor: 7.640

7.  Expression of mdr1 and gst-pi in human breast tumours: comparison to in vitro chemosensitivity.

Authors:  W N Keith; S Stallard; R Brown
Journal:  Br J Cancer       Date:  1990-05       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.